COX-2 and the kidney

Journal of Cardiovascular Pharmacology

Volumn 47, Issue SUPPL. 1, 2006, Pages

  Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase; Hypertension; Prostaglandin; Renin

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE; DISEASE EXACERBATION; EDEMA; ENZYME INHIBITION; ENZYME METABOLISM; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN RELEASE; REVIEW; SODIUM EXCRETION;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HOMEOSTASIS; HUMANS; KIDNEY; RENIN;

EID: 33750318519     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200605001-00007     Document Type: Review

References (91)

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(Suppl 56):18-24.
2. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001;21:1-15.
3. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther. 2000;7:63-74.
4. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance?. Drug Saf. 1997;17:277-289.
5. Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38:700-704.
6. Atta MG, Whelton A. Acute renal papillary necrosis induced by ibuprofen. Am J Ther. 1997;4:55-60.
7. Sturmer T, Elseviers MM, De Broe ME. Nonsteroidal antiinflammatory drugs and the kidney. Curr Opin Nephrol Hypertens. 2001;10:161-163.
8. Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex. Am J Physiol. 1978;235:F451-F457.
9. Komhoff M, Grone HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997;272:F460-F468.
10. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-2510.
11. Guan Y, Chang M, Cho W, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol. 1997;273:F18-F26.
12. Khan KN, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol. 1998;26:612-620.
13. Khan KN, Stanfield KM, Harris RK, et al. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail. 2001;23:321-330.
14. Nantel F, Meadows E, Denis D, et al. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett. 1999;457:475-477.
15. Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol. 2004;12:71-74.
16. Komhoff M, Jeck ND, Seyberth HW, et al. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int. 2000;58:2420-2424.
17. Yang T, Schnermann JB, Briggs JP. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol. 1999;277:F1-F9.
18. Ferguson S, Hebert RL, Laneuville O. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol. 1999;10:2261-2271.
19. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31:588-598.
20. Smith WL, Sonnenburg WK, Allen ML, et al. The biosynthesis and actions of prostaglandins in the renal collecting tubule and thick ascending limb. Adv Exp Med Biol. 1989;259:131-147.
21. Stokes JB. Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol. 1981;240:F471-F480.
22. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol. 1998;274:F481-F489.
23. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
24. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465-1470.
25. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002;72:50-61.
26. Svendsen KB, Bech JN, Sorensen TB, et al. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000;56:383-388.
27. Kammerl MC, Nusing RM, Schweda F, et al. Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin Pharmacol Ther. 2001;70:468-474.
28. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
29. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-1928.
30. Whelton A. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J Hypertens. 2002;20(Suppl 6):S31-S35.
31. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300.
32. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
33. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs. 1996;51:179-187.
34. Hocherl K, Endemann D, Kammerl MC, et al. Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol. 2002;136:1117-1126.
35. Yao B, Harris RC, Zhang MZ. Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1767-R1773.
36. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69.
37. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol. 2002;89:3D-9D.
38. FDA. Arthritis Advisory Committee Meeting. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf (February 2001). Accessed December 2001.
39. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7:159-175.
40. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
41. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
42. White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-934.
43. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:161-168.
44. Persson AE, Salomonsson M, Westerlund P, et al. Macula densa cell function. Kidney Int Suppl. 1991;32:S39-S44.
45. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol. 1998;274:R263-R279.
46. Salomonsson M, Gonzalez E, Westerlund P, et al. Chloride concentration in macula densa and cortical thick ascending limb cells. Kidney Int Suppl. 1991;32:S51-S54.
47. Lorenz JN, Weihprecht H, Schnermann J, et al. Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol. 1991;260:F486-F493.
48. Cheng HF, Wang JL, Zhang MZ, et al. Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000;106:681-688.
49. Yang T, Park JM, Arend L, et al. Low chloride stimulation of PGE2 release and COX-2 expression in a mouse Macula densa cell line. J Biol Chem. 2000;275:37922-37929.
50. Cheng HF, Harris RC. Cyclooxygenase-2 expression in cultured cortical thick ascending limb of Henle increases in response to decreased extracellular ionic content by both transcriptional and post-transcriptional mechanisms. Role of p38-mediated pathways. J Biol Chem. 2002;277:45638-45643.
51. Cheng HF, Wang JL, Zhang MZ, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest. 1999;103:953-961.
52. Yang T, Endo Y, Huang YG, et al. Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol. 2000;279:F819-F825.
53. Zhang MZ, Harris RC, McKanna JA. Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc Natl Acad Sci USA. 1999;96:15280-15285.
54. Traynor TR, Smart A, Briggs JP, et al. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol. 1999;277:F706-F710.
55. Peti-Peterdi J, Komlosi P, Fuson AL, et al. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest. 2003;112:76-82.
56. Harding P, Sigmon DH, Alfie ME, et al. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension. 1997;29:297-302.
57. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension. 1999;34:96-101.
58. Stubbe J, Jensen BL, Bachmann S, et al. Cyclooxygenase-2 contributes to elevated renin in the early postnatal period in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1179-R1189.
59. Hocherl K, Kammerl M, Kees F, et al. Role of renal nerves in stimulation of renin, COX-2, and nNOS in rat renal cortex during salt deficiency. Am J Physiol Renal Physiol. 2002;282:F478-F484.
60. Kammerl MC, Nusing RM, Seyberth HW, et al. Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch. 2001;442:842-847.
61. Wolf K, Castrop H, Hartner A, et al. Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa. Hypertension. 1999;34:503-507.
62. Cheng HF, Wang JL, Zhang MZ, et al. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol. 2001;280:F449-F456.
63. Cheng HF, Wang SW, Zhang MZ, et al. Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am J Physiol Regul Integr Comp Physiol. 2002;283:R638-R646.
64. Athirakul K, Kim HS, Audoly LP, et al. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int. 2001;60:2324-2329.
65. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des. 2000;6:1737-1753.
66. Reinalter SC, Jeck N, Brochhausen C, et al. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2002;62:253-260.
67. Kleta R, Basoglu C, Kuwertz-Broking E. New treatment options for Bartter's syndrome. N Engl J Med. 2000;343:661-662.
68. Schnermann J. Cyclooxygenase-2 and macula densa control of renin secretion. Nephrol Dial Transplant. 2001;16:1735-1738.
69. Welch WJ, Wilcox CS. Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure. Effects of salt intake. J Clin Invest. 1997;100:2235-2242.
70. Welch WJ, Wilcox CS. Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa. J Clin Invest. 1992;89:1857-1865.
71. Dunn MJ. Prostaglandin I2 and the kidney. Arch Mal Coeur Vaiss. 1989;82(Spec No 4):27-31.
72. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal antiinflammatory drugs. Am J Med. 2001;111:64-67.
73. Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension. 2000;36:276-281.
74. Roig F, Llinas MT, Lopez R, et al. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension. 2002;40:721-728.
75. Castrop H, Schweda F, Schumacher K, et al. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol. 2001;12:867-874.
76. Rossat RJ, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76-84.
77. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000;133:1-9.
78. Chen BH. COX-2 inhibitors and renal function in elderly people. CMAJ. 2000;163:604.
79. Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25:537-544.
80. Woywodt A, Schwarz A, Mengel M, et al. Nephrotoxicity of selective COX-2 inhibitors. J Rheumatol. 2001;28:2133-2135.
81. Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003;64:1328-1334.
82. Papaioannides D, Bouropoulos C, Sinapides D, et al. Acute renal dysfunction associated with selective COX-2 inhibitor therapy. Int Urol Nephrol. 2001;33:609-611.
83. Akhund L, Quinet RJ, Ishaq S. Celecoxib-related renal papillary necrosis. Arch Intern Med. 2003;163:114-115.
84. Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet. 2001;357:1946-1947.
85. Ortiz M, Mon C, Fernandez MJ, et al. Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib. Nefrologia. 2005;25:39-43.
86. Gunja N, Graudins A, Dowsett R. Lithium toxicity: a potential interaction with celecoxib. Intern Med J. 2002;32:494.
87. Slordal L, Samstad S, Bathen J, et al. A life-threatening interaction between lithium and celecoxib. Br J Clin Pharmacol. 2003;55:413-414.
88. Miyataka M, Rich KA, Ingram M, et al. Nitric oxide, antiinflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension. 2002;39:785-789.
89. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res. 2001;43:429-436.
90. Celotti F, Durand T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Lipid Mediat. 2003;71:147-162.
91. Alvaro-Gracia JM. Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford). 2004;43(Suppl 1):i21-i25.